Gerda Engholm

Gerda Engholm

Auto-generated profile, based on publicly available information

Gerda Engholm


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
GEGerda Engholm
Gerda Engholm
JFJacques Ferlay
Jacques Ferlay
NCNiels Christensen
Niels Christensen
FBFreddie Bray
Freddie Bray
MGMarianne L. Gjerstorff
Marianne L. Gjerstorff
HSHans Henrik Storm
Hans Henrik Storm
The NORDCAN database and program (www.ancr.nu) include detailed information and results on cancer incidence, mortality and prevalence in each of the Nordic countries over five decades and has lately been supplemented with predictions of cancer incidence and mortality; future extensions include the incorporation of cancer survival estimates. Material and methods. The data originates from the national cancer registries and causes of death registries in Denmark, Finland, Iceland, Norway, Sweden, and Faroe Islands and is regularly updated. Presently 41 cancer entities are included in the common dataset, and conversions of the original national data according to international rules ensure comparability. Results. With 25 million inhabitants in the Nordic countries, 130 000 incident cancers are reported yearly, alongside nearly 60 000 cancer deaths, with almost a million persons living with a cancer diagnosis. This web-based application is available in English and in each of the five Nordic national languages. It includes comprehensive and easy-to-use descriptive epidemiology tools that provide tabulations and graphs, with further user-specified options available. Discussion. The NORDCAN database aims to provide comparable and timely data to serve the varying needs of policy makers, cancer societies, the public, and journalists, as well as the clinical and research community.

1 March 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
UYU Yousaf
U Yousaf
MCM-Lm Christensen
M-Lm Christensen
GEG Engholm
G Engholm
HSHans Henrik Storm
Hans Henrik Storm
Compared to the general population, the suicide risk among Danish cancer patients diagnosed in 1971–1986 was increased by 50% for men and 30% for women. We updated the earlier study to evaluate both long-term and recent trends in the suicide risk. Cancer patients with a first cancer diagnosed between 1971 and 1999 in Denmark were followed-up for completed suicide through 1999. Excluding nonmelanoma skin cancer, 564 508 cancer patients were included and 1241 suicides observed. Both the standardised mortality ratio (SMR) of suicide relative to the general population and the suicide rates were analysed with Poisson regression methods. The overall SMR was increased to 1.7 (95% CI. 1.6–1.9) for men and 1.4 (95% CI: 1.3–1.5) for women. Following the cancer diagnosis, the suicide risk was highest in the first 3 months for men and between months 3 and 12 for women. The risk was higher for nonlocalised cancer and for cancers with perceived poor prognosis. Breast cancer patients had a higher risk than other cancer patients with similar good prognosis. The suicide rates among cancer patients decreased with calendar time, but less so than the rates in the general population. The suicide risk among cancer patients has not decreased as much as in the Danish population and reasons for this should be explored. Breast cancer might be believed by patients to be more life threatening than it is. Assessment and treatment of depression could improve the quality of life for cancer patients who suffer from unrecognised depressions and in turn reduce the risk of suicide in cancer patients.


23 April 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
GEGerda Engholm
Gerda Engholm
AKAnne Mette T. Kejs
Anne Mette T. Kejs
DBDavid H. Brewster
David H. Brewster
MGMaria Gaard
Maria Gaard
LHLars Holmberg
Lars Holmberg
HSHans Henrik Storm
Hans Henrik Storm
A deficit in colorectal cancer survival in Denmark and in the UK compared to Sweden, Norway and Finland was found in the EUROCARE studies. We set out to explore if these differences still exist. Patients diagnosed with colorectal cancer as their first invasive cancer at age 15–89 in the period 1994–2000 were identified using data from 11 cancer registries in the UK and from four Nordic countries. Five‐year relative period survival using deaths in 1999–2000 following cancers diagnosed in 1994–2000 was analysed with excess mortality risk modelling. Follow‐up time since diagnosis with age as an effect‐modifier in the first half year was the most important factor with the highest excess risk of death immediately after diagnosis and with higher age and decreasing with length of follow‐up. Variations between countries were bigger in the first half year following diagnosis than in the interval 0.5–5 years with about 30% higher risk in UK and Denmark. The differences between countries are still substantial and the order has not changed, even if the five year relative survival has improved since the EUROCARE studies. Patient management, diagnostics, and comorbidity likely explain the excess deaths in UK and Denmark during the first 6 months. The effect of stage and quality of management and treatment should be examined in population based studies with detailed patient information. Use of more detailed age‐intervals than conventionally applied in survival studies proved to be important in statistical modelling and is recommended for future studies.

1 January 2010 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
GEGerda Engholm
Gerda Engholm
MGMette Gislum
Mette Gislum
FBFreddie Bray
Freddie Bray
THTimo Hakulinen
Timo Hakulinen
Comparable data on cancer incidence and mortality in Denmark, Finland, Iceland, Norway, and Sweden are available for analysis through a collaboration of the national Cancer Registries via the NORDCAN website (http://ancr.nu). In the continued spirit of Nordic collaborative research, a number of studies examining trends in cancer survival are published in this journal. Material and methods. The data were divided into eight 5-year periods by sex in five Nordic countries. Age-standardised 5-year relative survival ratios and excess mortality rates in the short-term (first month and 1–3 months following diagnosis), and the long-term (2–5 years after diagnosis) were calculated, as were age-specific 5-year relative survival using cohort-survival methods. A hybrid method combining the cohort and period methods was used for the period 1999–2003 as not all patients were followed for five years. Age-standardisation used the International Cancer Survival Standard, and calculation of expected deaths used country-specific population mortality rates. Results. The data series constitutes 3 360 397 tumours among 3 160 802 patients followed up for death through 2006 for 39 different cancer sites diagnosed in the years 1964–2003. The paper describes the data, exclusions and imputations, design and analysis, age structure and standardisation procedures, follow-up, and case-mix adjustment methods. Conclusion. The strengths of this study include the overall comparability and quality of the data, the national coverage, and the length of the time series. Collecting and analysing data from the five Nordic countries for 39 different cancer sites over 40 years in a systematised and comparable way is a major undertaking. A thorough description of the analyses, definitions and exclusions in the survival study, supplemented with corresponding information on cancer incidence and mortality is needed for appropriate interpretation and comparison between countries, and between and within cancer sites. This information must be made available to provide appropriate interpretation of the site-specific results.

1 January 2010 in Acta Oncologica
Verified
Journal Article
Closed access
PDF file
GEGerda Engholm
Gerda Engholm
THTimo Hakulinen
Timo Hakulinen
MGMette Gislum
Mette Gislum
LTLaufey Tryggvadóttir
Laufey Tryggvadóttir
ÅKÅsa Klint
Åsa Klint
HSHans Henrik Storm
Hans Henrik Storm
Background. Previous studies have shown systematic differences between the Nordic Countries in population-based relative survival following a kidney or urinary bladder cancer diagnosis. Comparison of bladder cancer over time and between Nordic registries is complicated by variable coding practices with respect to the inclusion of in situ cases with invasive tumours. Material and methods. Five-year relative survival of patients with urinary cancer diagnosed in the Nordic countries 1964–2003 and followed up for death through 2006 was studied and contrasted with developments in incidence and mortality. Results. The survival following bladder cancer was higher than for kidney cancer and highest for men. Survival increased over the years in all countries, more for kidney cancer than bladder cancer. For Danish kidney cancer patients, the rate of increase over all the years has been lower than in the other countries, especially among women, resulting in a survival in Denmark some 10–20% points lower than elsewhere in 1999–2003. Danish bladder cancer patient survival was in the last period 4% points lower among men and 10% points lower among women than in the other Nordic countries. The differences were mainly found in the first year following diagnosis, where a higher excess mortality in Denmark was observed. Survival decreased with higher age at diagnosis. Conclusion. The increasing 5-year relative survival in all the Nordic countries for both kidney and bladder cancer are promising, but for kidney cancer a higher percentage detected coincidentally during an imaging investigation for other diseases could play a role. Denmark had the lowest survival, despite their known practice of including benign conditions with invasive bladder cancers. The lower Danish survival after kidney and bladder cancer in the first year after diagnosis could be due to later diagnosis on average, a higher co-morbidity from smoking-related diseases, and perhaps, less adequate cancer treatment and management in Denmark.